无BAK的曲伏前列素治疗正常眼压性青光眼患者3年的效果。
Effects of BAK-free travoprost treatment for 3 years in patients with normal tension glaucoma.
作者信息
Inoue Kenji, Iwasa Mayumi, Wakakura Masato, Tomita Goji
机构信息
Inouye Eye Hospital, Tokyo, Japan.
出版信息
Clin Ophthalmol. 2012;6:1315-9. doi: 10.2147/OPTH.S33816. Epub 2012 Aug 15.
BACKGROUND
The purpose of this study was to evaluate the effects of benzalkonium (BAK)-free travoprost monotherapy administered for 3 years on intraocular pressure and visual field performance.
METHODS
The intraocular pressure of 76 patients with normal tension glaucoma was monitored every 1-3 months. A Humphrey visual field test was performed every 6 months after treatment and compared with the results before treatment. Visual field performance was also evaluated by trend and event analysis.
RESULTS
Thirty cases discontinued within 3 years. Mean intraocular pressure after 3 years of travoprost treatment (14.1 ± 2.4 mmHg) was significantly lower than that before treatment (16.8 ± 2.6 mmHg, P < 0.0001). There was no change in the mean deviation and pattern standard deviation as measured by Humphrey visual field test after 3 years of treatment compared with before treatment. Visual field performance was worse in one patient (2.8%) by trend analysis and five patients (13.9%) by event analysis. Treatment was discontinued in six cases (7.9%) due to the appearance of adverse reactions.
CONCLUSION
BAK-free travoprost monotherapy was effective in reducing intraocular pressure for at least 3 years; however, visual field performance worsened in 2.8%-13.9% of patients with normal tension glaucoma.
背景
本研究旨在评估不含苯扎氯铵（BAK）的曲伏前列素单药治疗3年对眼压和视野表现的影响。
方法
每1 - 3个月监测76例正常眼压性青光眼患者的眼压。治疗后每6个月进行一次汉弗莱视野测试，并与治疗前结果进行比较。还通过趋势分析和事件分析评估视野表现。
结果
30例患者在3年内停药。曲伏前列素治疗3年后的平均眼压（14.1±2.4 mmHg）显著低于治疗前（16.8±2.6 mmHg，P < 0.0001）。治疗3年后，与治疗前相比，汉弗莱视野测试测得的平均偏差和模式标准差没有变化。通过趋势分析，1例患者（2.8%）视野表现变差；通过事件分析，5例患者（13.9%）视野表现变差。6例患者（7.9%）因出现不良反应而停药。
结论
不含BAK的曲伏前列素单药治疗至少3年对降低眼压有效；然而，2.8% - 13.9% 的正常眼压性青光眼患者视野表现变差。
Zotero 插件